What are the key financial updates from this filing?

The primary financial update is the announcement of Synopsys' results for the second fiscal quarter ended May 5, 2012, as presented in an attached press release. This release includes both GAAP and non-GAAP financial figures, with management providing detailed explanations for their non-GAAP adjustments.

Why does Synopsys use non-GAAP financial measures, and what do they exclude?

Synopsys uses non-GAAP measures to offer investors a more insightful view of its operational performance and liquidity, believing these measures better reflect ongoing business trends. They exclude items such as amortization of acquired intangible assets, stock-based compensation expenses, acquisition-related costs, and certain infrequent or unusual items like facility restructuring charges and tax benefits from IRS settlements. Management uses these alongside GAAP measures for internal decision-making and external comparisons.

What is the significant leadership change announced in this report?

The most significant leadership change is the appointment of Dr. Chi-Foon Chan as Co-Chief Executive Officer, effective May 21, 2012. He will share CEO duties with Dr. Aart de Geus, who remains CEO and also takes on the role of Chairman of the Board. This move necessitated an amendment to the company's bylaws.

Will Dr. Chi-Foon Chan's compensation change with his new role?

According to the filing, no changes to Dr. Chi-Foon Chan's compensation were made at the time of his appointment as Co-Chief Executive Officer.

SNPS 8-K: Earnings & Results, Leadership Changes & More

Summary

This Form 8-K filing by Synopsys, Inc. (SNPS) on May 23, 2012, primarily announces the company's financial results for the second fiscal quarter ended May 5, 2012, as detailed in an attached press release. Investors should note that the press release includes non-GAAP financial measures, which exclude items such as amortization of acquired intangibles, stock compensation, and acquisition-related costs. Synopsys management utilizes these non-GAAP measures to provide supplemental insights into operational performance and liquidity, believing they offer a clearer view of ongoing business trends. In addition to financial results, the report also details a significant leadership change: the appointment of Dr. Chi-Foon Chan as Co-Chief Executive Officer, serving alongside the current CEO, Dr. Aart de Geus, who will also continue as Chairman of the Board. This leadership transition was effective May 21, 2012, and the company's bylaws were amended to reflect this co-CEO structure. No immediate changes to Dr. Chan's compensation were noted.

Key Highlights

1Synopsys announced its financial results for the second fiscal quarter ended May 5, 2012.
2The financial results press release (Exhibit 99.1) includes non-GAAP financial measures, providing an alternative view to GAAP results.
3Key non-GAAP exclusions include amortization of acquired intangibles, stock compensation, and acquisition-related costs, aimed at highlighting operational performance.
4Dr. Chi-Foon Chan was appointed Co-Chief Executive Officer, effective May 21, 2012.
5Dr. Aart de Geus will continue as CEO and also serve as Chairman of the Board, while Dr. Chan will serve as Co-CEO.
6Synopsys' Amended and Restated Bylaws were updated to accommodate the co-CEO leadership structure.
7No immediate changes to Dr. Chi-Foon Chan's compensation were reported in connection with his Co-CEO appointment.

SYNOPSYS INC 8-K Report, Financial Results (May 23, 2012)

Summary

Key Highlights

Frequently Asked Questions